 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ABO2011 / Suzhou Abogen Biosci
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Phase ?/? Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors (clinicaltrials.gov) - Jul 8, 2024
P1/2, N=218, Recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
N=160 --> 218 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
- ||| ABO2011 / Suzhou Abogen Biosci
Enrollment status, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Phase ?/? Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors (clinicaltrials.gov) - Apr 24, 2024
P1/2, N=160, Recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
N=160 --> 218 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026 Enrolling by invitation --> Recruiting | Phase classification: P1 --> P1/2 | N=40 --> 160 | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2025
- ABO2011 / Suzhou Abogen Biosci
Preliminary safety, antitumor activity, and pharmacodynamics of intratumoral ABO2011 (IL-12 mRNA) in patients with advanced solid tumors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6341;
P1
The pharmacodynamic changes were as expected. Promising preliminary antitumor activities of the single agent and the pharmacodynamic profiles support further investigation of ABO2011 in combination with immune checkpoint inhibitor.
- | ABO2011 / Suzhou Abogen Biosci
Enrollment status, Combination therapy, Monotherapy, Metastases: Phase ?/? Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors (clinicaltrials.gov) - Nov 3, 2023
P1, N=40, Enrolling by invitation, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Promising preliminary antitumor activities of the single agent and the pharmacodynamic profiles support further investigation of ABO2011 in combination with immune checkpoint inhibitor. Recruiting --> Enrolling by invitation
- || ABO2011 / Suzhou Abogen Biosci
New P1 trial, Combination therapy, Monotherapy, Metastases: Phase ?/? Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors (clinicaltrials.gov) - Oct 17, 2023
P1, N=40, Recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
- | ABO2011 / Suzhou Abogen Biosci
Enrollment open, Metastases: ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy (clinicaltrials.gov) - Jun 22, 2022
P1, N=60, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- | ABO2011 / Suzhou Abogen Biosci
New P1 trial, Metastases: ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy (clinicaltrials.gov) - May 26, 2022
P1, N=60, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences